Kiora Pharmaceuticals Inc KPRX.OQ KPRX.O is expected to show a rise in quarterly revenue when it reports results on November 7 (estimated) for the period ending September 30 2024
The Encinitas California-based company is expected to report revenue of $7 thousand, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Kiora Pharmaceuticals Inc is for a loss of 76 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Kiora Pharmaceuticals Inc is 27.00, above its last closing price of $3.52.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -0.87 | -0.86 | -0.53 | Beat | 38.1 |
Mar. 31 2024 | -0.59 | -0.59 | 3.42 | Beat | 675.8 |
Dec. 31 2023 | -3.69 | -3.77 | -4.23 | Missed | -12.3 |
Sep. 30 2023 | -3.09 | -3.18 | -8.01 | Missed | -151.9 |
Jan. 1 0001 | -6.63 | -9.59 | -7.11 | Beat | 25.9 |
Mar. 31 2023 | -15.41 | -9.00 | 40.7 | ||
Jan. 1 0001 | -20.04 | -22.14 | -15.81 | Beat | 28.6 |
Sep. 30 2022 | -33.12 | -34.51 | -54.30 | Missed | -57.3 |
This summary was machine generated November 6 at 14:29 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。